Vestmark Advisory Solutions Inc. Sells 3,121 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Vestmark Advisory Solutions Inc. lessened its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 25.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,065 shares of the medical equipment provider’s stock after selling 3,121 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in BioLife Solutions were worth $235,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new stake in BioLife Solutions during the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the 3rd quarter valued at $28,000. Quest Partners LLC bought a new stake in BioLife Solutions during the 3rd quarter valued at $57,000. Smartleaf Asset Management LLC boosted its position in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 950 shares in the last quarter. Finally, Summit Global Investments acquired a new stake in shares of BioLife Solutions in the 3rd quarter worth $228,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $25.83 on Monday. The business has a fifty day moving average of $26.65 and a 200 day moving average of $25.49. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.37 and a beta of 2.04. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the business posted ($0.21) EPS. As a group, research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. The trade was a 2.68 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,978 shares of company stock worth $322,724. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the subject of a number of recent analyst reports. KeyCorp raised their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. HC Wainwright raised their price objective on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.